TG Therapeutics, Inc.TGTX
Recorded
TG Therapeutics, Inc. 12th Annual Cantor Fitzgerald Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration31 min
Key takeaways
- TG Therapeutics is nearing the completion of its fourth full year of sales for BRAMV, approved for relapsing forms of MS, and is tracking toward a billion-dollar run rate before the end of the year.
- The company is focused on building its commercial franchise, expanding marketing efforts particularly around patient engagement, and advancing clinical programs including an enhanced trial to simplify BRAMV IV onboarding and a subcutaneous (subQ) phase 3 study with data expected later this year or early next year.
- TG Therapeutics is committed to the IV business despite developing a subQ formulation and aims to become the leading CD20 IV drug in the market.
- The company highlighted the strength of its BRAMV patents, with composition of matter patent protection until 2042 and another patent expiring in 2045, covering the glycosylation pattern critical to the product's biological activity.
- TG is also exploring pipeline indications including treatment-resistant schizophrenia and myasthenia gravis (MG), with ongoing phase 2 and other studies.
- The company noted that Roche is pulling back support for its IV product Rocuso and pushing patients to its subQ and at-home products, which creates opportunities for BRAMV in the IV market.
- BRAMV IV is currently priced at a 20-25% discount to Ocrelizumab, and TG believes biosimilars will need to price even lower to compete, with limited payer willingness to switch patients to biosimilars.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring